Li, J., Jiang, H., Huang, M., Wan, L., Bai, C., Zheng, Y., Zhou, A., Dai, J., Zhou, J., Zhao, R., Mou, Y., Yuan, X., Wu, N., Dou, L., Fei, D., Qin, X., Qin, C. (2026). Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4045